JamesAPoseyIIIMD

Oncology • Philadelphia, PA

Gastrointestinal Cancer, Hematologic Oncology

Professor, Director of GI Program Dept of Oncology Co-Leader GI Program SKCC

Join to view full profile

Dr. Posey is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Posey's full profile

Already have an account?

Office
1025 Walnut Street
Suite 700
Philadelphia, PA 19107
Phone+1 215-503-6442

Education & Training

Georgetown University HospitalFellowship, Medical Oncology, 1994 - 1996
MedStar Health/Georgetown University HospitalResidency, Internal Medicine, 1991 - 1994
Howard University College of MedicineClass of 1991

Certifications & Licensure

MD State Medical License 2024 - 2025
PA State Medical License 2016 - 2024
NJ State Medical License 2017 - 2023
DE State Medical License 2017 - 2021
AL State Medical License 1997 - 2016
DC State Medical License 1995 - 1998

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Clinical Trials

ISIS 2503 in Treating Patients With Advanced Cancer of the Pancreas Start of enrollment: 2000 Jul 01
Completed
Phase 2
Irinotecan and Taxotere With Radiotherapy as Preoperative Treatment in Resectable Esophageal Cancer Start of enrollment: 2002 Jan 01
Completed
Phase 2
Pharmacogenomically Selected Treatment for Gastric and Gastroesophageal Junction (GEJ) Tumors Start of enrollment: 2007 Aug 01
Completed
Phase 2
Evaluation of Patients With Bulky GIST Using Sunitinib Start of enrollment: 2009 Oct 01
Terminated
Not Applicable
Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer Start of enrollment: 2011 Sep 30
Terminated
Phase 1, Phase 2
Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced Pancreatic Cancer Start of enrollment: 2019 May 10
Active, not recruiting
Phase 3
A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies Start of enrollment: 2019 Nov 06
Recruiting
Phase 1
Join now to see all

Publications & Presentations

PubMed

1 citations
Early outcomes of MR-guided SBRT for patients with recurrent pancreatic adenocarcinoma.
Spencer J Poiset, Sophia Shah, Louis Cappelli, Pramila Anné, Karen E Mooney
Radiation Oncology. 2024-05-29
1 citations
Phase 1 trial of navitoclax and sorafenib in patients with relapsed or refractory solid tumors with hepatocellular carcinoma expansion cohort.
Oluwadunni E Emiloju, Jun Yin, Emily Koubek, Joel M Reid, Mitesh J Borad
Investigational New Drugs. 2024-02-01
2 citations
Feasibility of a Text Messaging-Integrated and Chatbot-Interfaced Self-Management Program for Symptom Control in Patients With Gastrointestinal Cancer Undergoing Chemo...
Sameh Gomaa, James Posey, Babar Bashir, Atrayee Basu Mallick, Eleanor Vanderklok
JMIR Formative Research. 2023-11-10

Lectures

Debate Moderator
ASCO Annual Meeting 2019 - Chicago, IL - 6/3/2019

Press Mentions

‘I Had 18 Months to Live, I’m Still Fighting Colon Cancer’April 12th, 2023

Grant Support

UAB 0282 GemcitabineNational Center For Research Resources2006
Rebeccamycin In Hepatabiliary CancersNational Center For Research Resources2004
Mentored Patient Oriented Research Career Development AwNational Center For Research Resources2000–2004
Taxotere W/ Continuous Infusion Topotecan In Advanced MalignanciesNational Center For Research Resources1999–2002
PNU 214936 In Advanced Adenocarcinomas Of The BreastNational Center For Research Resources1999–2002
GEM 231 Infusion In Patients With Refractory Solid TumorsNational Center For Research Resources2000
Antivitronectin Receptor Humanized Monoclonal Antibody In Metastatic CancerNational Center For Research Resources1999–2000